Advertisement

A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache

Published:February 04, 2013DOI:https://doi.org/10.1016/j.ajem.2012.10.014

      Abstract

      Objective

      The objective of this study is to compare the efficacy and tolerability of intravenous valproic acid (iVPA) with intramuscular metoclopramide + subcutaneous (SQ) sumatriptan for prolonged acute migraine.

      Background

      Intravenous valproic acid has been explored as a possible treatment of acute migraine. Sumatriptan and newer generation triptans are also effective for migraine. However, iVPA has not yet been compared with triptans in head-to-head studies.

      Methods

      Patients presenting with moderate to severe intensity migraine without aura were randomized to receive either 400 mg of iVPA or 10 mg intramuscular metoclopramide + 6 mg SQ sumatriptan (30 patients in each study arm). The severity of headache and other associated symptoms such as photophobia and phonophobia were assessed at baseline and after 20 minutes and 1, 2, 4, and 24 hours. The primary end point was to compare the efficacy of the 2 study treatments in relieving headache from moderate-severe to none-mild and of other associated symptoms within a period of 24 hours.

      Results

      Pain relief from severe or moderate to mild or none was obtained in 53.3% of subjects in the iVPA arm and 23.3% in the metoclopramide + sumatriptan arm at 1 hour following treatment (P = .033), whereas 60% and 30% reported pain relief at 2 hour (P = .037). There was no other significant difference in alleviation of associated migraine symptoms between the 2 arms. No serious adverse effects were noted.

      Conclusion

      Treatment with iVPA was more effective than metoclopramide + SQ sumatriptan during the first 2 hours in patients with a prolonged migraine.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tepper S.J.
        • Spears R.C.
        Acute treatment of migraine.
        Neurol Clin. 2009; 27: 417-427
        • Goadsby P.J.
        • Lipton R.B.
        • Ferrari M.D.
        Migraine—current understanding and treatment.
        N Engl J Med. 2002; 346: 257-270
        • Stovner L.
        • Hagen K.
        • Jensen R.
        • Katsarava Z.
        • Lipton R.B.
        • Scher A.
        • et al.
        The global burden of headache: a documentation of headache prevalence and disability worldwide.
        Cephalalgia. 2007; 27: 193-210
        • Bigal M.E.
        • Lipton R.B.
        The epidemiology burden, and comorbidities of migraine.
        Neurol Clin. 2009; 27: 321-334
        • Stewart W.F.
        • Bigal M.E.
        • Lipton R.B.
        Lifetime migraine incidence. Results from the American Migraine Prevalence and Prevention study.
        Headache. 2005; 46: 52-55
        • Edwards K.R.
        • Norton J.
        • Behnke M.
        Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.
        Headache. 2001; 41: 976-980
        • Silberstein S.D.
        Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
        Neurology. 2000; : 55
        • Loder E.
        Triptan therapy in migraine.
        N Engl J Med. 2010; 363: 63-70
        • Tfelt-Hansen P.
        • Vries P.D.
        • Saxena P.R.
        Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.
        Drugs. 2000; 60: 1259-1287
        • Callaham M.
        • Raskin N.
        A controlled study of dihydroergotamine in the treatment of acute migraine headache.
        Headache. 1986; 26: 168-171
        • Derry C.
        • Derry S.
        • Moore R.
        Sumatriptan (oral route of administration) for acute migraine attacks in adults (Review).
        Cochrane Database Syst Rev. 2012;
        • Freitag F.
        • Finlayson G.
        • Rapoport A.
        • Elkind A.
        • Diamond M.
        • Unger J.
        • et al.
        Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
        Headache. 2007; 47: 519-530
        • Pascual J.
        • Cabarrocas X.
        Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better.
        Headache. 2002; 42: 28-31
        • Goadsby P.J.
        • Zanchin G.
        • Geraud G.
        • Klippel N.D.
        • Diaz-Insa S.
        • Gobel H.
        • et al.
        Early vs. non-early intervention in acute migraine - 'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.
        Cephalalgia an international journal of headache. 2008; 28: 383-391
        • Evers S.
        • Afra J.
        • Frese A.
        • Goadsby P.J.
        • May A.
        • Sandor P.S.
        EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force.
        Eur J Neurol. 2009; 16: 968-981
        • Colman I.
        • Brown M.D.
        • Innes G.D.
        • Grafstein E.
        • Roberts T.E.
        • Rowe B.H.
        Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.
        BMJ. 2004; 329: 1369-1373
        • Klapper J.
        Divalproex sodium in migraine prophylaxis: a dose-controlled study.
        Cephalalgia. 1997; 17: 103-108
        • Mathew N.T.
        • Kailasam J.
        • Meadors L.
        • Chernyschev O.
        • Gentry P.
        Intravenous valproate sodium (Depacon) aborts migraine rapidly: a preliminary report.
        Headache. 2000; 40: 720-723
        • Cutrer F.
        • Limmroth V.
        • Moskowitz M.
        Possible mechanisms of valproate in migraine prophylaxis.
        Cephalalgia. 1997; 17: 93-100
        • Shahien R.
        • Saleh S.A.
        • Bowirrat A.
        Intravenous sodium valproate aborts migraine headaches rapidly.
        Acta Neurol Scand. 2011; 123: 257-265
        • Leniger T.
        • Pageler L.
        • Stude P.
        • Diener H.C.
        • Limmroth V.
        Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks.
        Headache. 2005; 45: 42-46
        • Tanen D.A.
        • Miller S.
        • French T.
        • Riffenburgh R.H.
        intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
        Ann Emerg Med. 2003; 41: 847-853
        • Lampl C.
        • Huber G.
        • Haas S.
        • Rittberger G.
        • Diener H.
        Difference in triptan effect in patients with migraine and early allodynia.
        Cephalalgia. 2008; 28: 1031-1038
        • Weatherall M.W.
        • Telzerow A.J.
        • Cittadini E.
        • Kaube H.
        • Goadsby P.J.
        Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache.
        Neurology. 2010; 75: 1098-1103
        • Todd K.H.
        • Funk K.G.
        • Funk J.P.
        • Bonacci R.
        Clinical significance of reported changes in pain severity.
        Ann Emerg Med. 1996; 27: 485-489
        • Gallagher E.J.
        • Liebman M.
        • Bijur P.E.
        Prospective validation of clinically important changes in pain severity measured on a visual analog scale.
        Ann Emerg Med. 2001; 38: 633-638
        • Stillman M.J.
        • Zajac D.
        • Rybicky L.A.
        Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
        Headache. 2004; 44: 65-69
        • Schwartz T.H.
        • Karpitskiy V.V.
        • Sohn R.S.
        Intravenous valproate sodium in the treatment of daily headache.
        Headache. 2002; 42: 519-522
        • Norton J.
        Use of intravenous valproate sodium in status migraine.
        Headache. 2000; 40: 755-757
        • Kostic M.A.
        • Gutierrez F.J.
        • Rieg T.S.
        • Moore T.S.
        • Gendron R.T.
        A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.
        Ann Emerg Med. 2010; : 56
        • Friedman B.W.
        • Corbo J.
        • Lipton R.B.
        • Bijur P.E.
        • Esses D.
        • Solorzano C.
        • et al.
        A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines.
        Neurology. 2005; 64: 463-468
        • Akpunonu B.E.
        • Mutgi A.B.
        • Federman D.J.
        • Volinsky F.G.
        • Brickman K.
        • Davis R.L.
        • et al.
        Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study.
        Ann Emerg Med. 1995; 25: 464-469
        • Meredith J.T.
        • Wait S.
        • Brewer K.L.
        A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine.
        Am J Emerg Med. 2003; 21: 173-175
        • Burke-Ramirez P.
        • Asgharnejad M.
        • Webster C.
        • Davis R.
        • Laurenza A.
        Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: a comparison between ethnic groups.
        Headache. 2001; 41: 873-882